(VCYT) Veracyte, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VCYT) Veracyte, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Veracyte, Inc. BCG Matrix helps you see how the company’s products or business units may rank across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Afirma GSC thyroid leader
Afirma is Veracyte, Inc.’s flagship thyroid test for indeterminate nodules, and it stayed a core growth driver in 2025. The test sits in a large, recurring diagnostic market and supports Veracyte’s leading branded franchise, which is why it fits the BCG Star profile. Strong share plus steady clinical demand keep Afirma central to cash flow and expansion.
Afirma Xpression Atlas add-on
Afirma Xpression Atlas expands Veracyte, Inc.'s thyroid workflow beyond a simple benign-or-suspicious call by adding genomic insight that can guide next steps. That lifts the clinical value of the franchise and helps protect share in a high-volume diagnostic category. In BCG terms, it fits a Star-supporting add-on because it strengthens a leading platform and can raise test utility per patient.
Decipher Prostate Biopsy
Decipher Biopsy is Veracyte’s core genomic classifier for prostate cancer risk, and its use fits a large U.S. market with about 300,000 new cases a year. In a precision-oncology space that keeps expanding in 2025-2026, its strong brand and clinical adoption support Star status. It can still scale as more men use tissue-based risk tools before treatment decisions.
Decipher Radical Prostatectomy
Decipher Radical Prostatectomy extends Veracyte, Inc.'s prostate franchise into the post-surgery setting, so it can capture testing after prostate removal as well as before treatment. That widens share across the care pathway, and in a market with about 299,010 new U.S. prostate cancer cases expected in 2026, it fits a Star profile because it can keep growing in a large base.
- Moves into post-prostatectomy care
- Raises share across the full pathway
- Targets a very large cancer market
Core thyroid and prostate franchise mix
Afirma and Decipher are Veracyte, Inc.'s core thyroid and prostate growth engines, and they fit the Star bucket because they combine strong clinical proof, broad payer coverage, and repeat use by specialists. In Veracyte, Inc.'s 2024 reporting, Afirma and Decipher together remained the main revenue drivers, with total company revenue at about $422 million and adjusted EBITDA near $86 million, showing scale and operating leverage.
- Afirma anchors thyroid testing demand
- Decipher drives prostate testing growth
- Both support reimbursement and physician loyalty
- Together, they form the clearest Star cluster
The mix matters because these two products reinforce each other in market trust: more evidence supports more payer access, which helps keep volume sticky. That makes the franchise the most defensible part of Veracyte, Inc.'s portfolio, even as new tests still need time to match its commercial reach.
Veracyte’s 2025-2026 Growth Stars: Afirma and Decipher
Afirma and Decipher remain Veracyte, Inc.'s clear Stars in 2025-2026: they sit in large, growing precision-dx markets, have strong specialist adoption, and keep driving the core revenue base. Veracyte reported about $422 million revenue in 2024, with these two franchises still the main growth engines into 2025.
| Star | Why it fits | Latest signal |
|---|---|---|
| Afirma | Thyroid leader | Core growth driver |
| Decipher | Prostate leader | Large 2026 market |
What is included in the product
Detailed Word Document
BCG matrix of Veracyte, Inc. highlights Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
BCG Matrix view for Veracyte, Inc. to quickly spot stars, cash cows, and laggards for smarter portfolio decisions.
Reference Sources
Provides a clear source trail for Veracyte, Inc., helping users verify key claims fast and make more confident decisions.
Cash Cows
Prosigna Breast Cancer Assay
Prosigna is Veracyte, Inc.’s mature breast cancer recurrence assay, built on the PAM50 gene signature and used in early-stage, hormone-receptor-positive disease. In a slower-growing, established market, it fits the Cash Cow profile: steady demand, lower investment needs, and dependable cash generation that can help fund Veracyte, Inc.’s newer growth bets.
Envisia Genomic Classifier
Envisia Genomic Classifier targets interstitial lung disease, a narrow but high-value niche where the diagnostic need is clear and repeat use is limited. In BCG terms, it fits a Cash Cow profile if share stays stable, because it is more established than Veracyte, Inc.’s newer pipeline programs. ILD covers 200+ disorders, so even modest share can support durable revenue.
Prosigna licensed markets
Prosigna licensed markets fit Cash Cow economics: Veracyte gets recurring international royalty revenue with limited field spend, so margins stay attractive while growth is steadier than new U.S. launches. The segment is a mature, lower-capex asset that should keep producing cash even as Veracyte pushes faster-growing domestic tests.
Technology and collaboration revenue
Veracyte, Inc.’s technology and collaboration revenue from Johnson & Johnson, Acerta Pharma, and CareDx can act like a Cash Cow because it brings in steadier non-product cash with limited operating strain. These deals fit the box when Veracyte keeps R&D and support costs low versus the fee stream.
- Steady non-product inflows
- Low incremental operating effort
- Supports cash flow stability
Established reimbursed diagnostics base
Veracyte, Inc.'s reimbursed tests turn into a Cash Cow once they are embedded in routine care: servicing costs fall, so each added test lifts cash conversion even if growth slows. In 2024, Veracyte reported $394.4 million in revenue and about 72% gross margin, which shows the economics of a mature reimbursed base. Mature workflows like Afirma and Decipher are the cash engine.
- Reimbursement locks in repeat use
- Incremental servicing cost drops
- Cash conversion improves as volume scales
- Mature workflows fit Cash Cow logic
Veracyte’s Cash Cows Keep Cash Flowing
Veracyte, Inc.’s Cash Cows are its mature assays and licensing streams: Prosigna, Envisia, and recurring partner revenue. These assets need less spend than newer tests, so they keep generating cash and help fund growth bets. In 2024, Veracyte, Inc. reported $394.4 million revenue and about 72% gross margin, showing strong cash conversion from the mature base.
| Cash Cow asset | Why it fits |
|---|---|
| Prosigna | Mature, steady demand |
| Envisia | Established niche use |
| Licensing revenue | Recurring, low spend |
What You See Is What You Get
Veracyte, Inc. Reference Sources
The Veracyte, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages, no hidden changes—just the full, ready-to-use report. Download it instantly and use it for analysis, presentations, or strategic planning. What you preview is what you get.
Dogs
Immunoscore Colon Cancer
Colon cancer diagnostics are crowded, with dozens of competing tissue, blood, and gene-expression tests chasing the same patients. If Immunoscore Colon Cancer keeps limited uptake, it cannot build scale or pricing power, which fits a Dog in BCG terms. With colorectal cancer still causing about 1.9 million new cases worldwide each year, the need is big, but Veracyte's share here can still stay small.
Percepta Genomic Sequencing Classifier
Percepta Genomic Sequencing Classifier targets lung-cancer risk, but it has not scaled like Afirma or Decipher. Veracyte reported 2025 revenue of about $300 million, while Percepta still sits in a small, more competitive niche, which limits monetization. Unless adoption rises fast, it fits Dog territory in the BCG matrix.
Percepta Nasal Swab Test
The Percepta Nasal Swab Test is still a niche offering inside Veracyte, Inc.’s BCG Matrix, so it fits Dogs if physician adoption stays weak. The nasal swab format is useful, but it needs broad, repeat use to justify higher spend; without that scale, returns stay thin. That matters because Veracyte’s 2025 business still depends on tests that can win routine clinician use, not just novelty.
Low-volume lung assay variants
Low-volume lung assay variants are a Dogs item for Veracyte, Inc. in the BCG Matrix because they bring weak scale and low operating leverage. Small sales volumes make field support, lab setup, and reimbursement work less efficient, so margins stay thin.
They’re usually better kept narrow than expanded, since each extra SKU adds cost faster than revenue.
- Low volume, low leverage
- Higher support cost per test
- Best kept tightly focused
Non-core assay extensions
Veracyte, Inc.’s non-core assay extensions fit the Dog bucket because weak reimbursement makes scaling hard and drains R&D and sales time. The company does not break out standalone revenue for these extensions, which itself signals limited economic weight versus core tests like Decipher, which drove most of 2025 growth. Low payoff plus fixed launch costs means poor capital use.
- Weak payer coverage limits adoption.
- Development spend can outstrip returns.
- Core assays deserve priority.
- Dogs should be cut or shelved.
Veracyte’s Dog Assets: Small, Weak, and Hard to Scale
Veracyte, Inc.'s Dog assets are small, crowded, and hard to scale. Percepta and niche lung or colon tests have weak uptake, so they add cost more than cash. In 2025, Veracyte reported about $300 million revenue, but these low-volume assays still lacked clear pricing power or strong reimbursement. Best path: keep them narrow or cut them.
| Dog asset | 2025 signal | BCG read |
|---|---|---|
| Percepta | Small niche | Dog |
| Low-volume assays | Thin margins | Dog |
| Non-core extensions | Weak coverage | Dog |
Question Marks
Percepta Genomic Atlas
Percepta Genomic Atlas is a future lung-cancer treatment decision tool, but it is still not proven in routine care, so it fits Veracyte, Inc. as a Question Mark. Lung cancer is a huge need area: non-small cell lung cancer makes up about 85% of cases, and lung cancer caused about 1.8 million deaths worldwide in 2022. Growth potential is real, but clinical uptake must still be shown.
LymphMark lymphoma subtyping
LymphMark targets a real need: lymphoma subtyping often drives treatment choice, and molecular tests can speed that call. Veracyte is still treating it as a future diagnostic, not a proven revenue engine. That makes it a Question Mark in the BCG Matrix until adoption and reimbursement become visible.
Envisia nCounter version
Envisia on the nCounter system could widen Veracyte, Inc.'s technical reach by using a more established molecular workflow, which may help labs adopt it faster.
Still, any platform shift needs fresh analytical validation and clinical proof, and payers and pulmonologists must accept it before volumes scale.
That mix of upside and uncertainty is why Envisia nCounter fits the Question Marks bucket in the BCG Matrix.
C2i MRD expansion
C2i MRD sits in a fast-growing precision-oncology niche, but Veracyte, Inc. has not yet proven meaningful share, so it still fits the Question Mark box. The upside is real if scaling works, since MRD is moving from niche testing toward broader post-treatment monitoring. Right now, the key issue is adoption, not demand.
- High-growth category
- Share still unproven
- Upside depends on scale
Future companion diagnostics partnerships
Veracyte, Inc.’s companion diagnostics partnerships are Question Marks because they can scale fast only if trials, regulatory review, and payer uptake all click. These collaborations add optionality for new assays, but until a partner program turns into approved, reimbursed revenue, the cash payoff stays uncertain.
- High upside, low current certainty.
- Success depends on trial and FDA wins.
- Reimbursement decides real commercial scale.
Veracyte’s Question Marks: Big Potential, Unproven Scale
Veracyte, Inc.’s Question Marks are assays with real market need but limited proof of scale. Percepta, LymphMark, Envisia nCounter, and C2i MRD sit in high-growth areas, yet adoption, reimbursement, and durable revenue are still unproven.
| Asset | Why Question Mark |
|---|---|
| Percepta | Not routine care |
| C2i MRD | Share unproven |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.